Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck & Co., Inc. stock is treading water just below the $100 mark on Wednesday, December 10, 2025, as investors weigh a rich pipeline and fresh analyst upgrades against looming patent and pricing pressures. The day’s news flow is dominated by dividend chatter, options “whale” activity, new institutional ownership disclosures, and fresh signs that competition to flagship cancer drug Keytruda is getting real.

Dividend Investing · NYSE:MRK · Pharmaceuticals
Merck (MRK) Stock Today – December 8, 2025: Pipeline Bets, Cidara Deal and Vaccine Policy Risks

Merck (MRK) Stock Today – December 8, 2025: Pipeline Bets, Cidara Deal and Vaccine Policy Risks

Merck & Co., Inc. is back in the spotlight. As of the afternoon of December 8, 2025, Merck shares trade around $98–99, down about 1% on the day and modestly below their recent 52‑week high of $105.84 reached in late November. That pullback comes after a powerful rebound from a May low near $76, driven by excitement over new cardiovascular and respiratory drugs, plus a $9.2 billion flu‑drug acquisition — even as investors remain focused on the looming 2028 patent cliff for Keytruda and fresh regulatory headwinds.Finviz+2Reuters+2
8 December 2025
··
Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Merck & Co., Inc. — the U.S. pharmaceutical company behind blockbuster cancer drug Keytruda and HPV vaccine Gardasil — has just wrapped up a busy early-December news cycle. The company closed a multi‑billion‑dollar debt offering, secured fresh regulatory wins in its cardiopulmonary and animal-health franchises, boosted its dividend, and simultaneously ran into a new patent roadblock for its subcutaneous Keytruda injection in Germany. PR Newswire+4Wikipedia+4Stock Titan+4
7 December 2025
···
Merck (MRK) Stock Outlook on December 4, 2025: Dividend Hike, Legal Setback and New Growth Drivers

Merck (MRK) Stock Outlook on December 4, 2025: Dividend Hike, Legal Setback and New Growth Drivers

As of the close on December 4, 2025, Merck & Co., Inc. shares finished at $100.86, down about 1.4% on the day, with after‑hours trading essentially flat around $100.83. The stock sits near the upper end of its 52‑week range of $73.31–$105.84, with a market value of roughly $250 billion, a trailing P/E around 13.3 and a forward P/E just under 12.MarketBeat+3StockAnalysis+3StockAnalysis+3
4 December 2025
··
Dow Jones Soars 664 Points as Fed Cut Hopes Ignite Dow 30 Rally — Merck and Home Depot Lead November 25, 2025 Surge

Dow Jones Soars 664 Points as Fed Cut Hopes Ignite Dow 30 Rally — Merck and Home Depot Lead November 25, 2025 Surge

The Dow Jones Industrial Average roared higher on Tuesday, November 25, 2025, with the Dow 30 jumping 664.18 points, or 1.43%, to 47,112.45, as investors doubled down on expectations that the Federal Reserve will cut interest rates at its December meeting. The S&P 500 added 0.91% to 6,765.88, while the tech‑heavy Nasdaq Composite gained 0.67% to 23,025.59. Small caps outperformed, with the Russell 2000 up about 2.1%. MarketScreener+2San Mateo Daily Journal+2
25 November 2025
···
Dow 30 Today (24 November 2025): Merck and Caterpillar Lead 200‑Point Dow Jones Rally on Fed Rate‑Cut Bets

Dow 30 Today (24 November 2025): Merck and Caterpillar Lead 200‑Point Dow Jones Rally on Fed Rate‑Cut Bets

On Monday, 24 November 2025, the Dow Jones Industrial Average climbed 202.86 points, or 0.44%, to 46,448.27, kicking off the holiday‑shortened week with a strong risk‑on tone. The rally was powered by healthcare and industrial heavyweights such as Merck, Caterpillar, IBM and Nvidia, while tech‑driven enthusiasm sent the Nasdaq up 2.69% and the S&P 500 up 1.55%. Reuters+2Reuters+2
25 November 2025
·········
1 … 5 6 7 8
Follow on Google News
Add as preferred source Open in Google News